Samsung Biologics Q2 Earnings Climb – More Upside Than Valuation Signals Samsung Biologics has Buy consensus and strong results: revenue up 30%, operating profit up 23%, net income up 33%, with margins at 54% gross and 44% operating, while the stock trades below the average target of about 1.97M won. 2026년 10월 01일 English
LG Chem Earnings Rise After Profit Turnaround: Valuation Gap LG Chem is rated Buy as revenue and operating profit rose, net profit turned positive, but margins stay thin and ROE negative. Valuation gap vs targets may close if earnings momentum continues. 2026년 09월 18일 English
